US GLP-1 prescriptions weaken as tirzepatide’s share rises to 57.9%
Citi’s tracking shows that total US GLP-1 prescriptions have turned negative year over year, while tirzepatide continues to gain share. Oral Wegovy now accounts for 35% of the brand’s prescriptions; the rollout of new oral products is occurring alongside a weakening overall market.
Citi ·